BLLN
BillionToOne, Inc.
September 24, 2026 · intraday
- Rarity
- 1.83
- Peak move
- +11.67%
- Float cap
- $2.2B
BillionToOne is a molecular diagnostics company that uses a single-molecule next-generation sequencing platform to detect and quantify genetic targets in cell-free DNA from a blood draw. It develops prenatal tests, including UNITY for fetal risk assessment, and oncology liquid biopsy tests, Northstar Select and Northstar Response, for therapy selection and treatment monitoring. Its tests are sold to physicians, clinics, and healthcare providers to guide patient care.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
6 events · 3 from SEC or newswire · 0 timed with the moveinsider_saleBillionToOne officer and director David Tsao filed notice to sell 3,333 Class A shares at an average price of $125.00, a proposed sale valued at $416,625.
SEC144 0001959173-26-007109regulatory_approvalAn FDA advisory panel voted on Sept. 23, 2026 to back GRAIL's Galleri multi-cancer early detection blood test, 7-2 with one abstention on benefits outweighing risks, 6-4 on effectiveness, and unanimously on safety.
insider_saleBillionToOne SVP of Laboratory Operations John Roderick ten Bosch sold 1,416 Class A shares on Sept. 21, 2026 at an average price of $106.61 for about $150,960 under a Rule 10b5-1 plan, leaving him 23,635 shares; the transaction was also reported as a Form 144 notice to sell at $120.00.
peer_disclosureNatera said Japan's PMDA approved its Signatera ctDNA test as a companion diagnostic for bladder cancer, with launch expected in H1 2027.
insider_saleBillionToOne General Counsel, Chief Compliance Officer and Secretary Thomas P. Lynch sold 35,112 Class A shares on Sept. 17, 2026 at prices around $110.29-$110.36 for about $3.87 million, alongside option exercises of 70,224 shares, cutting his direct stake about 98% to 700 shares.
peer_disclosureNatera presented the largest lung-cancer MRD dataset to date at the IASLC 2026 World Conference on Lung Cancer in Seoul: 1,129 resected stage 1-3 NSCLC patients, with Signatera-positive patients showing about 5x higher risk of recurrence or death.